Abstract
The calcitonin receptor (CTR) is a class B G protein-coupled receptor that is a therapeutic target for the treatment of hypercalcaemia of malignancy, Paget's disease and osteoporosis. In primates, the CTR is subject to alternative splicing, with a unique, primate-specific splice variant being preferentially expressed in reproductive organs, lung and kidney. In addition, humans possess a common non-synonymous single-nucleotide polymorphism (SNP) encoding a proline/leucine substitution in the C-terminal tail. In low power studies, the leucine polymorphism has been associated with increased risk of osteoporosis in East Asian populations and, independently, with increased risk of kidney stone disease in a central Asian population. The CTR is pleiotropically coupled, though the relative physiological importance of these pathways is poorly understood. Using both COS-7 and HEK293 cells recombinantly expressing human CTR, we have characterized both splice variant and polymorphism dependent response to CTs from several species in key signalling pathways and competition binding assays. These data indicate that the naturally occurring changes to the intracellular face of CTR alter ligand affinity and signalling, in a pathway and agonist dependent manner. These results further support the potential for these primate-specific CTR variants to engender different physiological responses. In addition, we report that the CTR exhibits constitutive internalization, independent of splice variant and polymorphism and this profile is unaltered by peptide binding.
| Original language | English |
|---|---|
| Pages (from-to) | 111-129 |
| Number of pages | 19 |
| Journal | Biochemical Pharmacology |
| Volume | 148 |
| DOIs | |
| Publication status | Published - 1 Feb 2018 |
Keywords
- Calcitonin
- Calcitonin receptor
- G protein-coupled receptor
- Polymorphism
- Splice variant
Cite this
}
Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms. / Dal Maso, Emma; Just, Rasmus; Hick, Caroline; Christopoulos, Arthur; Sexton, Patrick M.; Wootten, Denise; Furness, Sebastian G.B.
In: Biochemical Pharmacology, Vol. 148, 01.02.2018, p. 111-129.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms
AU - Dal Maso, Emma
AU - Just, Rasmus
AU - Hick, Caroline
AU - Christopoulos, Arthur
AU - Sexton, Patrick M.
AU - Wootten, Denise
AU - Furness, Sebastian G.B.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - The calcitonin receptor (CTR) is a class B G protein-coupled receptor that is a therapeutic target for the treatment of hypercalcaemia of malignancy, Paget's disease and osteoporosis. In primates, the CTR is subject to alternative splicing, with a unique, primate-specific splice variant being preferentially expressed in reproductive organs, lung and kidney. In addition, humans possess a common non-synonymous single-nucleotide polymorphism (SNP) encoding a proline/leucine substitution in the C-terminal tail. In low power studies, the leucine polymorphism has been associated with increased risk of osteoporosis in East Asian populations and, independently, with increased risk of kidney stone disease in a central Asian population. The CTR is pleiotropically coupled, though the relative physiological importance of these pathways is poorly understood. Using both COS-7 and HEK293 cells recombinantly expressing human CTR, we have characterized both splice variant and polymorphism dependent response to CTs from several species in key signalling pathways and competition binding assays. These data indicate that the naturally occurring changes to the intracellular face of CTR alter ligand affinity and signalling, in a pathway and agonist dependent manner. These results further support the potential for these primate-specific CTR variants to engender different physiological responses. In addition, we report that the CTR exhibits constitutive internalization, independent of splice variant and polymorphism and this profile is unaltered by peptide binding.
AB - The calcitonin receptor (CTR) is a class B G protein-coupled receptor that is a therapeutic target for the treatment of hypercalcaemia of malignancy, Paget's disease and osteoporosis. In primates, the CTR is subject to alternative splicing, with a unique, primate-specific splice variant being preferentially expressed in reproductive organs, lung and kidney. In addition, humans possess a common non-synonymous single-nucleotide polymorphism (SNP) encoding a proline/leucine substitution in the C-terminal tail. In low power studies, the leucine polymorphism has been associated with increased risk of osteoporosis in East Asian populations and, independently, with increased risk of kidney stone disease in a central Asian population. The CTR is pleiotropically coupled, though the relative physiological importance of these pathways is poorly understood. Using both COS-7 and HEK293 cells recombinantly expressing human CTR, we have characterized both splice variant and polymorphism dependent response to CTs from several species in key signalling pathways and competition binding assays. These data indicate that the naturally occurring changes to the intracellular face of CTR alter ligand affinity and signalling, in a pathway and agonist dependent manner. These results further support the potential for these primate-specific CTR variants to engender different physiological responses. In addition, we report that the CTR exhibits constitutive internalization, independent of splice variant and polymorphism and this profile is unaltered by peptide binding.
KW - Calcitonin
KW - Calcitonin receptor
KW - G protein-coupled receptor
KW - Polymorphism
KW - Splice variant
UR - http://www.scopus.com/inward/record.url?scp=85039787770&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2017.12.016
DO - 10.1016/j.bcp.2017.12.016
M3 - Article
VL - 148
SP - 111
EP - 129
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
SN - 0006-2952
ER -